A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies.

被引：0
|
作者：
Shapira, Roni
Weber, Jeffrey S.
Geva, Ravit
Sznol, Mario
Kluger, Harriet M.
Wong, Deborah J. L.
Liang, Bertrand C.
机构：
[1] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[2] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[3] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[4] Yale New Haven Med Ctr, Yale Sch Med, 20 York St, New Haven, CT 06504 USA
[5] Yale New Haven Med Ctr, Smilow Canc Ctr, 20 York St, New Haven, CT 06504 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Kitov Pharma, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3094
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Gareth, Thomas Marbury
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CANCER RESEARCH, 2023, 83 (08)
  • [32] Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.
    Zhou, Fei
    Li, Wei
    Chen, Yu
    Lin, Jing
    Chen, Ling
    Zhang, Huishan
    Dong, Xiaorong
    Tong, Fan
    Zhang, Ruiguang
    Yin, Yongmei
    Liang, Yan
    Yang, Nong
    Hu, Sheng
    Zhuang, Wei
    Li, Tao
    Cai, Shengli
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Open-label, single-dose, phase I study evaluating the mass balance and pharmacolkinetics (PKs) of sunitinib (SU) in healthy male subjects
    Sherman, L.
    Peng, G.
    Patyna, S.
    Pool, W.
    Smeraglia, J.
    Bello, C. L.
    Garrett, M.
    Klamerus, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 116 - 116
  • [34] A PHASE I, SINGLE-DOSE, RANDOMIZED, OPEN-LABEL, CROSSOVER, RELATIVE BIOAVAILABILITY, AND FOOD EFFECT STUDY OF BELVARAFENIB IN HEALTHY SUBJECTS.
    Malhi, V.
    Monemi, S.
    Dolton, M.
    Kapp, A.
    Angelaud, R.
    Zhang, W.
    Eng-Wong, J.
    Sullivan, C.
    Mueller, L.
    Musib, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S43 - S43
  • [35] A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    du Bois, A.
    Huober, J.
    Stopfer, P.
    Pfisterer, J.
    Wimberger, P.
    Loibl, S.
    Reichardt, V. L.
    Harter, P.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 370 - 375
  • [36] Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
    Goldberg, Avram
    Geppert, Thomas
    Schiopu, Elena
    Frech, Tracy
    Hsu, Vivien
    Simms, Robert W.
    Peng, Stanford L.
    Yao, Yihong
    Elgeioushi, Nairouz
    Chang, Linda
    Wang, Bing
    Yoo, Stephen
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
  • [37] Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study
    Avram Goldberg
    Thomas Geppert
    Elena Schiopu
    Tracy Frech
    Vivien Hsu
    Robert W Simms
    Stanford L Peng
    Yihong Yao
    Nairouz Elgeioushi
    Linda Chang
    Bing Wang
    Stephen Yoo
    Arthritis Research & Therapy, 16
  • [38] A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
    Gao, Ling
    Yamamiya, Ikuo
    Pinti, Mark
    Rondon, Juan Carlos
    Marbury, Thomas
    Tomlinson, Gareth
    Makris, Lukas
    Hangai, Nanae
    Wacheck, Volker
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (09): : 1713 - 1724
  • [39] Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of Clostridium difficile toxin a human monoclonal antibody (CDA1)
    Taylor, Claribel P.
    Tummala, Sanjeev
    Molrine, Deborah C.
    Farrell, Richard J.
    Lembo, Anthony
    Hibberd, Patricia L.
    Davidson, Lisa
    Lowy, Israel
    Kelly, Ciaran P.
    GASTROENTEROLOGY, 2006, 130 (04) : A315 - A315
  • [40] Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
    Cohen, Fredric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 87 - 94
12345